{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-23-000092","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.708670+00:00","generated_at":"2026-06-09T04:43:37.065023+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ivonescimab shows 18-fold increased PD-1 binding affinity in presence of VEGF at SITC","bullets":["Poster at SITC 2023 details cooperative binding: 18x higher PD-1 affinity with VEGF present in vitro.","Tetravalent bispecific antibody designed for higher avidity in tumor microenvironment vs. healthy tissue.","Ongoing Phase III trials HARMONi (EGFR-mutated NSCLC) and HARMONi-3 (squamous NSCLC).","Over 950 patients treated with ivonescimab across studies in China, Australia, and Summit territories."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-23-000092","json":"https://secwatch.observer/filing/0001599298-23-000092.json","markdown":"https://secwatch.observer/filing/0001599298-23-000092.md","text":"https://secwatch.observer/filing/0001599298-23-000092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929823000092/0001599298-23-000092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929823000092/smmt-20231031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T04:43:37.065023+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}